Vukasin Paunovich Sells 44,394 Shares of LifeStance Health Group (NASDAQ:LFST) Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) CTO Vukasin Paunovich sold 44,394 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $10.85, for a total transaction of $481,674.90. Following the completion of the sale, the chief technology officer directly owned 247,446 shares in the company, valued at approximately $2,684,789.10. This represents a 15.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

LifeStance Health Group Stock Performance

NASDAQ LFST opened at $12.22 on Friday. The company has a market capitalization of $4.74 billion, a price-to-earnings ratio of 94.01 and a beta of 1.14. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.18. LifeStance Health Group, Inc. has a twelve month low of $4.77 and a twelve month high of $12.43. The stock has a fifty day simple moving average of $10.29 and a 200 day simple moving average of $8.19.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The company had revenue of $435.35 million for the quarter, compared to analyst estimates of $414.58 million. During the same period in the previous year, the firm earned ($0.01) earnings per share. The firm’s quarterly revenue was up 26.1% on a year-over-year basis. Sell-side analysts expect that LifeStance Health Group, Inc. will post 0.15 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on LFST shares. KeyCorp increased their price target on LifeStance Health Group from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. BTIG Research lifted their price objective on shares of LifeStance Health Group from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, August 7th. The Goldman Sachs Group started coverage on shares of LifeStance Health Group in a research report on Friday, June 5th. They set a “neutral” rating and a $9.00 target price on the stock. Canaccord Genuity Group raised their price target on shares of LifeStance Health Group from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Finally, Zacks Research downgraded shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.62.

Hedge Funds Weigh In On LifeStance Health Group

Institutional investors have recently modified their holdings of the company. Assetmark Inc. lifted its holdings in shares of LifeStance Health Group by 17.0% in the 1st quarter. Assetmark Inc. now owns 9,419 shares of the company’s stock worth $60,000 after purchasing an additional 1,367 shares in the last quarter. California State Teachers Retirement System raised its holdings in LifeStance Health Group by 1.6% during the fourth quarter. California State Teachers Retirement System now owns 125,682 shares of the company’s stock worth $885,000 after buying an additional 1,966 shares during the last quarter. Vident Advisory LLC raised its holdings in LifeStance Health Group by 12.7% during the second quarter. Vident Advisory LLC now owns 21,732 shares of the company’s stock worth $112,000 after buying an additional 2,447 shares during the last quarter. Xponance LLC lifted its stake in shares of LifeStance Health Group by 26.4% in the fourth quarter. Xponance LLC now owns 13,144 shares of the company’s stock valued at $93,000 after buying an additional 2,745 shares in the last quarter. Finally, Diversified Trust Co grew its holdings in shares of LifeStance Health Group by 14.8% during the first quarter. Diversified Trust Co now owns 21,532 shares of the company’s stock valued at $137,000 after buying an additional 2,770 shares during the last quarter. 85.50% of the stock is owned by institutional investors and hedge funds.

LifeStance Health Group News Roundup

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Analyst support remains favorable. Morgan Stanley reaffirmed its Buy rating on LFST, adding to a broader consensus view that includes six Buy ratings and an overall “Moderate Buy” recommendation. Morgan Stanley Reaffirms Buy Rating
• Positive Sentiment: Recent fundamentals are improving. LifeStance’s latest quarterly results exceeded analyst expectations, with earnings of $0.06 per share versus a $0.03 consensus estimate and revenue of $435.35 million versus expectations of $414.58 million. Revenue increased 26.1% year over year, supporting the stock’s momentum-investor appeal. LifeStance Weekly Momentum Analysis
• Positive Sentiment: Market momentum remains strong. LFST recently set a new 52-week high following an analyst upgrade, signaling continued investor optimism. However, the stock’s elevated price-to-earnings ratio of roughly 94 means future appreciation likely depends on sustained earnings growth. LifeStance Sets New 52-Week High
• Neutral Sentiment: Zacks highlighted LFST among low-leverage stocks that may appeal to investors seeking companies with resilient balance sheets amid market volatility. LifeStance’s debt-to-equity ratio is 0.18, but the article does not represent a material change to company guidance. Zacks Low-Leverage Stocks Article
• Negative Sentiment: Multiple insiders sold shares. Major shareholder TPG GP A sold 13.64 million shares for approximately $144.9 million. Separately, COO Lisa K. Miller sold about $519,845 of stock and CTO Vukasin Paunovich sold about $481,675. Each retained a sizable position, but the transactions could create concerns about profit-taking and near-term selling pressure. LifeStance Insider Sale Filing

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.